PCSK9 blocking agents reduce systemic levels of total cholesterol and LDL, affecting the risk of atherosclerosis but also reducing the supply of cholesterol by cancer cells [120,121] through the enhancement of apolipoprotein E receptor, CD36, β-secretase 1, and others [122,123]. Here, CD36 is linked to atherosclerosis.